ArticleCurrent topics in medicinal chemistry2026
Effect of Recombinant Tuxtide Intervention on DSS-induced Acute UC Mouse Model.
Article in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study is to investigate the differences in the therapeutic effects of recombinant GLP-2 and Lactobacillus plantarum L9, both alone and in combination, for treating UC, providing new directions for future acute UC therapy.
methodsThe GLP-2 homologous peptide from Amphiuma tridactylum species was screened via the NCBI database, and its advanced structure and molecular function were bioinformatically predicted. This fragment was then recombined into the plasmid pET-28a (+) and transformed into Escherichia coli Rosetta (BL21). IPTG induced the expression of the recombinant protein, which was purified, followed by thrombin cleavage to obtain Tuxtide peptides. These peptides were separated via Native PAGE and purified using Trition X-114 and dialysis methods. Acute UC model mice were established using 3% DSS. Changes in body weight and disease activity index scores during the medication period were recorded and analyzed. Colon length and spleen index of mice in each group were measured, and HE staining and colon histology scoring were performed. ELISA was used to detect myeloperoxidase and interleukin-1β in mouse colon tissue.
resultsCompared to the DSS group, the colon length of mice in all treatment groups improved, with significant effects observed in the Tuxtide and Tuxtide+L9 groups (P<0.05). Body weight in all treatment groups rebounded compared to the DSS group, and DAI scores decreased (P<0.05), with the Tuxtide group showing the best improvement in body weight. All treatment groups alleviated intestinal mucosal pathological damage to varying degrees compared to the DSS group, with the Tuxtide+L9 group showing the best anti-inflammatory effect, reducing colon histology scores and restoring intestinal crypts (P<0.1).
conclusionBoth Tuxtide alone and in combination with Lactobacillus plantarum L9 can alleviate symptoms in mice with acute ulcerative colitis.
Indexed as
Identifiers
40103474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.